Compound 60 has an extremely high affinity to MDM2 (Ki < 1 nM), powerful mobile activity, and a very good oral pharmacokinetic profile. Compound sixty is effective at accomplishing total and extended-Long lasting tumor regression in vivo and is also currently in phase I medical trials for most cancers treatment https://connervohcs.blogsidea.com/38063471/the-md-224-diaries